Abstract
Introduction: Recent research has shown that IL-6 receptor (IL-6R) inhibitors like tocilizumab and satralizumab are effective in reducing the relapse rate in patients with NMOSD. Areas covered: This review article explores current concepts in NMOSD management and focuses on IL-6R as a therapeutic target. The authors delve into the biological and immunological role of IL-6 in the pathogenesis of NMOSD. Further, the authors summarize the most recent findings on the use of anti-IL-6R monoclonal antibodies, tocilizumab and satralizumab, in the treatment of NMOSD. Expert opinion: A better understanding of the role of cytokines in NMOSD may provide the neurologist with novel therapies for this disease. IL-6R appears to be a central hub to NMOSD pathogenesis and a relevant therapeutic target.

This publication has 57 references indexed in Scilit: